Compare DNOW & BCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DNOW | BCRX |
|---|---|---|
| Founded | 1862 | 1986 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 2.4B |
| IPO Year | 2014 | 1995 |
| Metric | DNOW | BCRX |
|---|---|---|
| Price | $12.89 | $8.88 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 11 |
| Target Price | $16.67 | ★ $20.82 |
| AVG Volume (30 Days) | 2.4M | ★ 3.9M |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 381.40 |
| EPS | N/A | ★ 1.21 |
| Revenue | ★ $2,648,000,000.00 | $25,186,000.00 |
| Revenue This Year | $69.47 | N/A |
| Revenue Next Year | $8.01 | $12.55 |
| P/E Ratio | ★ N/A | $7.38 |
| Revenue Growth | ★ 25.68 | N/A |
| 52 Week Low | $10.94 | $6.00 |
| 52 Week High | $17.26 | $11.31 |
| Indicator | DNOW | BCRX |
|---|---|---|
| Relative Strength Index (RSI) | 63.37 | 46.11 |
| Support Level | $12.56 | $8.73 |
| Resistance Level | $16.19 | $9.14 |
| Average True Range (ATR) | 0.35 | 0.36 |
| MACD | 0.13 | -0.12 |
| Stochastic Oscillator | 97.30 | 23.59 |
Dnow Inc is a provider of energy and industrial solutions and a distributor of pipe, valves, and fittings (PVF) and pumps, as well as fabrication, assembly, and testing of process and production equipment. It provides a broad mix of products required to build and maintain essential infrastructure and operating equipment across upstream, midstream, gas utilities, downstream, energy transition, and industrial markets, along with value-added supply chain solutions and technical product expertise supported by digital offerings through its DigitalNOW and MRCGO e-commerce platforms. The company operates mainly under the DNOW and MRC brands and has three reportable segments: the United States, which generates the majority of revenue, Canada, and International.
BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, to block key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.